A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., ...
When the World Health Organization endorsed twice-yearly lenacapavir as a new option for HIV pre-exposure prophylaxis, much ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays ...
Health experts say that while lenacapavir is a major advance in HIV prevention, the twice-yearly injectable drug does not ...
The Centers for Disease Control and Prevention (CDC), on behalf of the U.S. Public Health Service (PHS), has released the 2025 Guidelines for the Management of Occupational Exposure to Human ...
(Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...
Georgia’s House of Representatives passed a bill Feb. 12 that would allow pharmacists to prescribe and administer HIV prevention medications, expanding access to care across the state. The bill, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results